ABBVAbbVie

$276.40+27% 1Y
Latest close: a new 52-week highOct 9, 2026what changed →

Is the business good?

Mixed

The checks split: 8 of 9 health tests passed and earnings fully cash-backed (1.6×), but margins compressing.

2 good, 1 to watch, 1 without data
Fundamental health (F-score)8 / 9SEC EDGAR · Dec 31, 2025

High fundamental quality. Nine pass/fail tests of year-over-year health from the filings.

Profits arrive as cash1.59×derived · Jun 30, 2026

Operating profit is fully backed by cash. Conversion is worsening vs a year ago.

Margin direction, 3 years−4.7 ptsderived

Positive operating leverage, operating profit is growing faster than sales, so margins widen as the business scales.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

FCF conversiontop 4% of the market
Leverage (Debt/EBITDA)behind 67% of the market

Where this answer is blind. The F-score rewards improvement, so an already-elite company can score mid-pack.

How good a business is ABBV?

AbbVie earns 23% on the capital it employs against a 9.0% cost of capital, so the business is worth more the bigger it gets.

23%

Return on invested capital · cost of capital 9.0% · 14 points above what the capital costs: growth creates value

Operating margin
26%

Operating margin · Drug Manufacturers - General median 24% · 12 months to Q2 2026

Cash conversion
1.59×

Cash conversion · 2.23× a year ago · operating cash flow covers the operating profit after tax

Share count, year on year
0.00%

Share count, year on year · flat: no meaningful dilution

Operating margin by fiscal year
YearOperating margin
FY202025%
FY202132%
FY202231%
FY202323%
FY202416%
FY202525%
Details›
Gross margin12 months to Q2 2026
71%
Operating margin12 months to Q2 2026
26%
Net margin12 months to Q2 2026
9.8%
Free cash flow margin
28%
R&D as % of revenue
15%
Revenue, trailing twelve months
$64.4B
Free cash flow, trailing twelve months
$18.2B
Net income, trailing twelve months
$6.31B
Return on invested capitaloperating profit after tax ÷ debt + equity − cash
23%

Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.